[Dyslipidemia in insulin resistance and its improvement by troglitazone].
Dyslipideia in insulin resistant state are characterized by 3 major components; increased triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and change in the composition of low-density lipoprotein (LDL) cholesterol particle which results in small-dense LDL. Insulin resistance is thought to lead to overproduction of very low-density lipoprotein (VLDL) cholesterol through the decreased peripheral lipoprotein lipase (LPL) activity, increased production of apolipoprotein B-100 and decreased clearance of remnant particles. Troglitazone, an insulin action enhancer, decreases the triglyceride level, increases HDL cholesterol level and decreases th proportion of small-dense LDL through the direct effect on lipoprotein metabolism. However, activation of PPAR-gamma is considered to possese potential atherogeneity and more closer examination is needed.
Yagi
K
K
2nd. Dept. Int. Med., School of Medicine, Kanazawa University.
Mabuchi
H
H
D008076:Cholesterol, HDL / Q000097:blood / Q000172:deficiency; D002839:Chromans / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D008076:Cholesterol, HDL; D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone